US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

登録

NVCR

NovoCure (NVCR)

NovoCure Ltd

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:NVCR

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/20	21 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NVCR	NovoCure Ltd
2024/05/02	20 : 01	Business Wire	Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon	NASDAQ:NVCR	NovoCure Ltd
2024/05/02	20 : 00	Business Wire	Novocure Reports First Quarter 2024 Financial Results	NASDAQ:NVCR	NovoCure Ltd
2024/04/24	23 : 45	Business Wire	Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024	NASDAQ:NVCR	NovoCure Ltd
2024/04/05	20 : 00	Business Wire	Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024	NASDAQ:NVCR	NovoCure Ltd
2024/04/01	20 : 00	Business Wire	Novocure to Report First Quarter 2024 Financial Results	NASDAQ:NVCR	NovoCure Ltd
2024/03/29	09 : 07	Business Wire	METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長	NASDAQ:NVCR	NovoCure Ltd
2024/03/29	02 : 51	Business Wire	Klinische Phase-3-Studie METIS erreicht primären Endpunkt und zeigt eine statistisch signifikante Verlängerung der Zeit bis zur intrakraniellen Progression bei Patient:innen mit Hirnmetastasen von nicht-kleinzelligem Lungenkrebs	NASDAQ:NVCR	NovoCure Ltd
2024/03/29	02 : 50	Business Wire	L’essai clinique de phase 3 METIS a atteint son critère principal, démontrant un allongement statistiquement significatif du délai médian jusqu’à la progression intracrânienne chez les patients porteurs de métastases cérébrales consécutives..	NASDAQ:NVCR	NovoCure Ltd
2024/03/27	20 : 00	Business Wire	METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer	NASDAQ:NVCR	NovoCure Ltd
2024/03/11	20 : 00	Business Wire	INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO	NASDAQ:NVCR	NovoCure Ltd
2024/03/06	06 : 08	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NVCR	NovoCure Ltd
2024/03/05	08 : 39	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NVCR	NovoCure Ltd
2024/03/05	07 : 56	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NVCR	NovoCure Ltd
2024/03/02	07 : 06	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NVCR	NovoCure Ltd
2024/03/02	07 : 01	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:NVCR	NovoCure Ltd
2024/03/01	06 : 43	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NVCR	NovoCure Ltd
2024/03/01	06 : 38	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NVCR	NovoCure Ltd
2024/03/01	06 : 35	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NVCR	NovoCure Ltd
2024/03/01	06 : 33	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NVCR	NovoCure Ltd
2024/03/01	06 : 30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NVCR	NovoCure Ltd
2024/02/22	21 : 11	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:NVCR	NovoCure Ltd
2024/02/22	21 : 06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NVCR	NovoCure Ltd
2024/02/22	21 : 05	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:NVCR	NovoCure Ltd
2024/02/22	21 : 00	Business Wire	Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update	NASDAQ:NVCR	NovoCure Ltd
2024/01/19	01 : 10	Dow Jones News	Novocure Shares Rise 17% After FDA Accepts Pre-Market Application	NASDAQ:NVCR	NovoCure Ltd
2024/01/18	21 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NVCR	NovoCure Ltd
2024/01/18	21 : 00	Business Wire	Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer	NASDAQ:NVCR	NovoCure Ltd
2024/01/13	06 : 57	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:NVCR	NovoCure Ltd
2024/01/12	07 : 15	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:NVCR	NovoCure Ltd

Showing the most relevant articles for your search:NASDAQ:NVCR

1 2 3 4 5 6 7 8 9 10 次へ >>

Health Care Select Sector

Financial Select Sector

US Dollar vs Euro

American Express

JP Morgan Chase

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約